Faecal microbiota transplantation as a treatment for inflammatory bowel disease: a national survey of adult and paediatric gastroenterologists in the UK

Article

Author: Mcilroy, James Roger ; Hold, Georgina Louise ; Hart, Ailsa ; Nalagatla, Niharika ; Hansen, Richard

BackgroundInterest in the use of faecal microbiota transplantation (FMT) in inflammatory bowel disease (IBD) has increased following outcomes in patients withClostridioides difficileinfection (CDI). While research exploring clinician awareness and attitude towards the use of FMT in CDI has been carried out, data for IBD are currently lacking.ObjectiveTo assess the perceptions of gastroenterologists and current practice relating to FMT as a treatment for IBD in the UK.DesignA web-based survey (Snap Survey software) was distributed through the British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition e-newsletters, and at the BSG Conference in June 2017.Results61 respondents completed the survey including presubspecialty trainees, gastroenterology specialists, associate specialists and consultants. Most (95%; n=58) respondents stated that they had heard of FMT being used as a treatment for IBD prior to participating in the survey. Based on current evidence, 34% (n=21) of respondents would consider using FMT in patients with IBD, 26% (n=16) would not and 39% (n=24) were undecided. When asked to rank routes of delivery in terms of preference, nasogastric tube was the least preferred route (39%; n=24) and oral capsule was the most preferred route (34%; n=21).ConclusionsA clear majority of UK gastroenterologists recognise FMT as a potential treatment for IBD; however, uptake is limited. A proportion of clinicians would consider FMT in IBD and the majority would consider entering patients into clinical trials. Future work should explore the utility and efficacy of oral FMT capsules in IBD.

News (Medical) associated with EnteroBiotix Ltd.

05 May 2025

·www.globenewswire.com

EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025

2 May 2025. EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that results from its IMPuLCE Phase 1b trial evaluating EBX-102, the Company’s next-generation full-spectrum microbiome product, in patients with liver cirrhosis will be shared as an oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place in Amsterdam, the Netherlands from 7-10 May 2025. Presentation Title: A multicentre randomised double-blind placebo-controlled phase 1b clinical trial evaluating the safety and mechanism of action of EBX-102, an oral pooled intestinal microbiota product, in liver cirrhosis: the IMPuLCE trial Presenter: Professor Ewan Forrest, Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK Session: Cirrhosis I: Cirrhosis & Complications Session date and Time: 09 May 2025, 08:45-09:00 CEST Presentation ID: OS-036 Location: Benhamou Room EnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its proprietary platform technology, EnteroBiotix creates next-generation therapies with differentiated characteristics designed to restore and enhance gut microbiome function. The company has established independent control over the supply chain for its drug formulations, with MHRA licensed manufacturing capabilities, and a donor programme called Number2®. EBX-102 is a next-generation, full-spectrum microbiome therapeutic composed of a high-diversity consortium of gut-derived microbes. Manufactured using the Company’s proprietary AMPLA™ technology, EBX-102 has a robust stability profile and is formulated as an off-white, odourless powder encapsulated into oral capsules. It is designed to deliver rapid, well-tolerated, and effective symptom relief for diseases associated with gut microbiome dysfunction, including liver cirrhosis and complications thereof, such as hepatic encephalopathy (HE). The content above comes from the network. if any infringement, please contact us to modify.

Microbial therapy

02 May 2025

·www.globenewswire.com

EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025

Glasgow, Scotland – 2 May 2025. EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that results from its IMPuLCE Phase 1b trial evaluating EBX-102, the Company’s next-generation full-spectrum microbiome product, in patients with liver cirrhosis will be shared as an oral presentation at the European Association for the Study of the Liver (EASL) Congress 2025, taking place in Amsterdam, the Netherlands from 7-10 May 2025. Oral Presentation DetailsPresentation Title: A multicentre randomised double-blind placebo-controlled phase 1b clinical trial evaluating the safety and mechanism of action of EBX-102, an oral pooled intestinal microbiota product, in liver cirrhosis: the IMPuLCE trialPresenter: Professor Ewan Forrest, Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UKSession: Cirrhosis I: Cirrhosis & ComplicationsSession date and Time: 09 May 2025, 08:45-09:00 CESTPresentation ID: OS-036Location: Benhamou Room About EnteroBiotixEnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its proprietary platform technology, EnteroBiotix creates next-generation therapies with differentiated characteristics designed to restore and enhance gut microbiome function. The company has established independent control over the supply chain for its drug formulations, with MHRA licensed manufacturing capabilities, and a donor programme called Number2®. About EBX-102EBX-102 is a next-generation, full-spectrum microbiome therapeutic composed of a high-diversity consortium of gut-derived microbes. Manufactured using the Company’s proprietary AMPLA™ technology, EBX-102 has a robust stability profile and is formulated as an off-white, odourless powder encapsulated into oral capsules. It is designed to deliver rapid, well-tolerated, and effective symptom relief for diseases associated with gut microbiome dysfunction, including liver cirrhosis and complications thereof, such as hepatic encephalopathy (HE). Media contacts EnteroBiotixDr James McIlroy, CEOinfo@enterobiotix.com ICR HealthcareNamrata Taak, Kris Lamenterobiotix@ICRHealthcare.com

Phase 1Microbial therapy

28 Apr 2025

·www.globenewswire.com

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025Glasgow, Scotland – 28 April 2025. EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class therapies for gut health, today announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in 122 adults with IBS-C has been selected for a late-breaking oral presentation at Digestive Disease Week® (DDW) 2025, to be held 3–6 May in San Diego, USA. Late-Breaker Presentation DetailsPresentation Title: A randomised, double-blind, placebo-controlled, phase II trial assessing the safety and efficacy of EBX-102-02, an oral full-spectrum intestinal microbiota product, in patients with irritable bowel syndrome with constipation; the TrIuMPH trialPresenter: Professor Anthony HobsonAbstract Number: 987bEmbargoed Until: 06 May 2025, 12:01 am PDTSession Title: DDW Clinical Science Late-Breaking Abstract PlenarySession date and Time: 06 May 2025, 08:15-08:30 am PDTLocation: Room 6A (SDCC) About EnteroBiotixEnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its proprietary platform technology, EnteroBiotix creates next-generation therapies with differentiated characteristics designed to restore and enhance gut microbiome function. The company has established independent control over the supply chain for its drug formulations, with MHRA licensed manufacturing capabilities, and a donor programme called Number2®. About EBX-102-02 EBX-102-02 is a next-generation, full-spectrum microbiome therapeutic composed of a high-diversity consortium of gut-derived microbes. Manufactured using the Company’s proprietary AMPLA™ technology, EBX-102-02 has a robust stability profile and is formulated as an off-white, odourless powder encapsulated into oral capsules. It is designed to deliver rapid, well-tolerated, and effective symptom relief for diseases associated with gut microbiome dysfunction, including irritable bowel syndrome (IBS). Media contacts EnteroBiotixDr James McIlroy, CEOinfo@enterobiotix.com ICR HealthcareNamrata Taak, Kris Lamenterobiotix@ICRHealthcare.com

Phase 2Microbial therapy

100 Deals associated with EnteroBiotix Ltd.

100 Translational Medicine associated with EnteroBiotix Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 30 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

EBX-102	Liver Cirrhosis More	Phase 2
EBX-102-02	Hematopoietic stem cell transplantation More	Phase 2
EBX-101	-	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis